UB
ITCI

UMB Bank’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

UMB Bank’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,622
Closed -$610K – 2198
2025
Q1 		$610K Buy
4,622
+2
+0% +$249 0.01% 385
2024
Q4 		$386K Hold
4,620
– – 0.01% 441
2024
Q3 		$338K Hold
4,620
– – 0.01% 473
2024
Q2 		$316K Hold
4,620
– – 0.01% 470
2024
Q1 		$320K Hold
4,620
– – 0.01% 480
2023
Q4 		$331K Sell
4,620
-36
-0.8% -$2.07K ﹤0.01% 478
2023
Q3 		$243K Hold
4,656
– – ﹤0.01% 523
2023
Q2 		$295K Hold
4,656
– – ﹤0.01% 499
2023
Q1 		$252K Hold
4,656
– – ﹤0.01% 527
2022
Q4 		$246K Hold
4,656
– – ﹤0.01% 537
2022
Q3 		$217K Hold
4,656
– – ﹤0.01% 585
2022
Q2 		$266K Sell
4,656
-400
-8% -$22.7K ﹤0.01% 569
2022
Q1 		$309K Buy
5,056
+400
+9% +$20.8K ﹤0.01% 564
2021
Q4 		$244K Buy
+4,656
New +$196K ﹤0.01% 628

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UMB Bank's ITCI Position: Q2 2025 in Review

UMB Bank sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 4,622 shares — an estimated $610K sold.

UMB Bank first reported a position in ITCI in Q4 2021 and held it in 14 quarters. The position peaked at $610K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • UMB Bank reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • UMB Bank sold 4,622 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $610K.
  • UMB Bank first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 14 quarters.
  • UMB Bank's Intra-Cellular Therapies Inc. position peaked at $610K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on UMB Bank's 13F filing for Q2 2025, filed 10 Jul 2025.